Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2010;14(5):446; author reply 446.
doi: 10.1186/cc9288. Epub 2010 Oct 26.

β-lactam antibiotics in continuous infusion in critically ill patients

Axel Jeurissen, Robert Rutsaert
Comment

β-lactam antibiotics in continuous infusion in critically ill patients

Axel Jeurissen et al. Crit Care. 2010.
No abstract available

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Witebolle X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14:R126. doi: 10.1186/cc9091. - DOI - PMC - PubMed
    1. Vincent JL, Rello J, Marshal J, Eliezer S, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. for the EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–2329. doi: 10.1001/jama.2009.1754. - DOI - PubMed
    1. Belgian Isepamycin Multicentre Group. Comparative in vitro activity of isepamycin and other antibiotics against gram-negative bacilli from intensive care units (ICU) in Belgium. Acta Clin Belg. 2001;56:307–315. - PubMed
    1. Roberts JA, Lipman J, Blot S, Rello J. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care. 2008;14:390–396. doi: 10.1097/MCC.0b013e3283021b3a. - DOI - PubMed
    1. Page MG, Heim J. Prospects for the next anti-Pseudomonas drug. Curr Opin Pharmacol. 2009;9:558–565. doi: 10.1016/j.coph.2009.08.006. - DOI - PubMed